Heron Therapeutics, Inc. (HRTX)

CARY, N.C. , Aug. 15, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that its Board of Directors (the "Board") has adopted a Section 382 rights plan (the "Rights Plan") designed to protect the availability and significant potential value of the Company's net operating loss carryforwards ("NOLs") and other tax attributes, which may be used to offset future taxable income. The Board unanimously approved the adoption of the Rights Plan.

Heron Therapeutics, Inc. (NASDAQ:HRTX ) Q2 2025 Earnings Conference Call August 8, 2025 8:30 AM ET Company Participants Craig Alexander Collard - CEO & Director Ira Duarte - Executive VP & CFO Mark E. Hensley - Executive VP & COO Melissa Jarel - Executive Director of Legal Conference Call Participants Brandon Richard Folkes - H.C.

Although the revenue and EPS for Heron Therapeutics (HRTX) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Heron Therapeutics (HRTX) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to a loss of $0.06 per share a year ago.

Heron (HRTX) Q2 Acute Care Jumps 56%

Generated Q2 2025 Net Revenue of $37.2 million and year-to-date revenue of $76.1 million; reaffirmed 2025 Net Revenue Guidance of $153 million - $163 million Delivered record year-to-date 2025 Adjusted EBITDA of $7.9 million, raised full-year 2025 Adjusted EBITDA Guidance from $4.0 million - $12.0 million to $9.0 million - $13.0 million ZYNRELEF ® unit demand grew 6.3% in Q2 2025 as compared to Q1 2025, with revenue impacted by a temporary wholesaler adjustment from the 400mg VAN transition; momentum building ahead of expanded commercial initiatives and dedicated sales team in Q3 2025 APONVIE ® unit demand grew 19% in Q2 2025 as compared to Q1 2025, supported by increased adoption in hospital systems and momentum building ahead of the newly launched dedicated sales team in Q3 2025 Completed comprehensive capital restructuring, reducing total debt from $175 million to $145 million and extending debt maturities to at least 2030, enhancing financial flexibility to support growth CARY, N.C. , Aug. 8, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for the three and six months ended June 30, 2025 and recent corporate updates.

CARY, N.C. , Aug. 8, 2025 Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the completion of a comprehensive capital restructuring designed to enhance the Company's financial flexibility, reduce total debt, and support long-term growth. The multi-faceted refinancing transaction consisted of the following key components: A new senior credit facility with Hercules Capital, Inc. (NYSE: HTGC), due in 2030, which provides $110.0 million in committed capital at closing and an additional $40.0 million in two $20.0 million tranches available upon achievement of certain milestones, to be drawn at the Company's discretion; An exchange agreement with the existing holder of Heron's 1.5% senior convertible notes due 2026 to retire outstanding principal, including repayment of approximately $125.0 million in cash and conversion of $25.0 million into common stock; Issuance and sale of $35.0 million of new 5.0% senior convertible notes due 2031; and A private placement with select investors for $27.7 million in gross proceeds through the issuance of common and preferred equity.

CARY, N.C. , Aug. 8, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that it has rescheduled its release of second quarter 2025 financial results and subsequent conference call. The Company will now host its conference call and live webcast on Friday, August 8, 2025, at 8:30 a.m.

CARY, N.C. , July 28, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Monday, August 11, 2025, at 4:30 p.m. ET to report second quarter 2025 financial results and discuss recent business highlights.

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

HRTX's Q1'25 earnings highlight Cinvanti as the top earner, but Zynrelef shows strong growth potential, with 60% growth in net sales vs Q1'24. HRTX reported net income of $2.6M and raised its full-year adjusted EBITDA guidance, but potential equity offerings to manage debt remain a risk. HRTX's CEO speaks of Zynrelef's multi-hundred-million-dollar potential, although it may take several more quarters of sales growth to convince the market of that potential.

Heron Therapeutics, Inc. (NASDAQ:HRTX ) Q1 2025 Earnings Conference Call May 6, 2025 8:00 AM ET Company Participants Melissa Jarel - Executive Director, Legal Craig Collard - Chief Executive Officer Ira Duarte - Executive Vice President, Chief Financial Officer Conference Call Participants Yuxi Dong - Jefferies Serge Belanger - Needham & Company Carl Byrnes - Northland Capital Markets Operator Good day, and thank you for standing by. Welcome to the Heron Therapeutics Q1 2025 Conference Call.

While the top- and bottom-line numbers for Heron Therapeutics (HRTX) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Heron Therapeutics (HRTX) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to loss of $0.02 per share a year ago.

Generated Q1 2025 Net Revenue of $38.9 million Delivered record Q1 2025 Adjusted EBITDA of $6.2 million Reached settlement with Mylan Pharmaceuticals, Inc., regarding the parties' CINVANTI ® and APONVIE ® patent litigations, including an agreed market entry date of June 1, 2032 Adjusted EBITDA guidance raised to a range of $4 - $12M for full year 2025 CARY, N.C. , May 6, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for the three months ended March 31, 2025, and highlighted recent corporate updates.